A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis

Phase 3 Unknown 368 enrolled Reistone Biopharma Company Limited

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled, multicenter Phase 3 study that will enroll approximately 368 subjects aged 18 to 75 years old with Moderately to Severely Active Ulcerative Colitis.

Timeline

Start: 2021-11-05
Primary completion: 2024-10-31
Completion: 2025-03-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SHR0302	Unknown	—	Oral

A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis

Summary

Timeline

Drugs

Indications